Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand names including Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate, SYMFI. Available dosage form: tablet, film coated.
Drug Details
- Generic Name
- Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
- Brand Names
- Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate, SYMFI
- Application Number
- ANDA212786
- Sponsor
- Laurus Labs Limited
- NDC Codes
- 3
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- EFAVIRENZ, LAMIVUDINE, TENOFOVIR DISOPROXIL FUMARATE
Indications and Usage
1 INDICATIONS AND USAGE Efavirenz, lamivudine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. Efavirenz, lamivudine and tenofovir disoproxil fumarate tablets are three-drug combination of efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors and are indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. ( 1 )